US Oncology Announces Election of Two New Members to Its Board of Directors

US Oncology Announces Election of Two New Members to Its Board of Directors

THE WOODLANDS, Texas, Sept. 24 /PRNewswire/ -- US Oncology, Inc., the nation's foremost cancer treatment and research network, announced today that Yon Yoon Jorden, former chief financial officer of four publicly traded companies, and Todd Vannucci, managing director with Morgan Stanley & Co., have joined the board of directors of US Oncology, Inc., and its parent company, US Oncology Holdings, Inc. Jorden has also been selected to serve as an audit committee member on each board.

Bruce Broussard, chief executive officer and chairman of the board for US Oncology, said that Jorden's extensive experience in corporate finance and strategy and Vannucci's finance and capital markets knowledge and background will make them valuable resources to management and the board as the company pursues its mission of advancing cancer care in America.

"Yon has been a key player in several health care payer organizations, and I look forward to her input and guidance as we continue to develop our payer-facing businesses and enhance our informatics capabilities," Broussard said. "Todd's financial knowledge and experience in private equity and capital markets will be a great asset to the board and management, and we are pleased to have the continued support and guidance of a representative from Morgan Stanley, our second largest stockholder."

Jorden, 54, most recently served as executive vice president and CFO of AdvancePCS, a publicly- traded provider of pharmacy benefits management. Previously she served as CFO of Informix, a technology company; Oxford Health Plans, a provider of managed health care services; and WellPoint Health Networks, a managed care company; each of which was a publicly traded company. She currently serves as a director of Magnatek, Inc., a manufacturer of digital power control systems, and Maxwell Technologies a manufacturer of energy storage and power delivery solutions. She is a Certified Public Accountant and also serves as a member of the advisory board of Methodist Hospital Dallas and the board of the Dallas Symphony Orchestra.

Vannucci, 48, is managing director of Morgan Stanley & Co. in its Morgan Stanley Principal Investments division. Mr. Vannucci has been with Morgan Stanley since 1998. Until this year he was in Morgan Stanley's Global Capital Markets division.

About US Oncology

US Oncology, Inc., headquartered in The Woodlands, Texas, works closely with physicians, payers, biotechnology, pharmaceutical and medical equipment manufacturers, to identify and deliver innovative services that enhance patient access to advanced cancer care. US Oncology supports one of the nation's foremost cancer treatment and research networks, accelerating the availability and use of evidence-based medicine and shared best practices.

US Oncology uses its expertise to support every aspect of the cancer care delivery system--from drug development to distribution and outcomes measurement--enabling the company to help increase the efficiency and safety of cancer care. According to the company's last quarterly earnings report, US Oncology is affiliated with 1,227 physicians operating in 468 locations, including 95 radiation oncology facilities in 39 states. For more information, visit the company's Web site, www.usoncology.com.

Suggested Articles

Genor Biopharma banked $160 million from the likes of Hillhouse and Temasek Holdings to advance its clinical-stage autoimmune and cancer programs.

Going from being the CSO of Bristol Myers Squibb to running one of the biggest cancer research organizations in the world is a major career shift.

Hahn made the commitment in a speech that called on the FDA to learn from the crisis to enact lasting policies that accelerate drug development.